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 Abstract 
 
Objectives: To develop a model for prediction of stillbirth based on a combination of maternal 
characteristics and medical history with first trimester biochemical and biophysical markers 
and evaluate the performance of screening of this model for all stillbirths and those due to 
impaired placentation and unexplained causes.  
 
Methods: This was a prospective screening study of 76,897 singleton pregnancies including  
76,629 live births and 268 (0.35%) antepartum stillbirths; 157 (59%) were secondary to 
impaired placentation and 111 (41%) were due to other or unexplained causes. Multivariate 
logistic regression analysis was used to determine if there was a significant contribution to 
prediction of stillbirth from the maternal factor-derived a priori risk, fetal nuchal translucency 
thickness (NT), ductus venosus pulsatility index for veins (DV-PIV), uterine artery pulsatility 
index (UT-PI) and maternal serum free ß-human chorionic gonadotrophin ((ß-hCG) and 
pregnancy associated plasma protein-A (PAPP-A). The significant contributors were used to 
derive a model for first-trimester prediction of stillbirth. 
 
Results: Significant contribution to prediction of stillbirth was provided by maternal factors, 
PAPP-A, UT-PI and DV-PIV. A model combining these variables predicted 40% of all 
stillbirths and 55% of those due to impaired placentation, at false positive rate of 10%; within 
the impaired placentation group the detection rate of stillbirth at <32 weeks’ gestation was 
higher than that of stillbirth at >37 weeks (64% vs 42%). 
 
Conclusions: A model based on maternal factors and first-trimester biomarkers can 
potentially predict more than half of subsequent stillbirths due to impaired placentation. The 
extent to which such stillbirths could be prevented remains to be determined.  
  
Introduction 
 
Risk factors for antepartum stillbirth include increasing maternal weight, Afro-Caribbean 
racial origin, assisted conception, cigarette smoking, diabetes mellitus, chronic hypertension 
systemic lupus erythematosus and antiphospholipid syndrome.1 In a prospectively screened 
population of 113,415 singleton pregnancies, including 396 (0.35%) antepartum stillbirths, 
multiple regression analysis was used to combine these risk factors into a model that 
predicted 26% of unexplained stillbirths and 31% of those due to impaired placentation, at 
false positive rate (FPR) of 10%; within the impaired placentation group the detection rate 
(DR) of stillbirth at <32 weeks’ gestation was higher than that of stillbirth at >37 weeks (38% 
vs 28%).1 
 
The objective of this study is to develop a model for prediction of stillbirth based on a 
combination of maternal characteristics and medical history with first trimester biochemical 
and biophysical markers and evaluate the performance of screening of this model for all 
stillbirths and those due to impaired placentation and unexplained causes.  
 
 
Methods 
 
Study population 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for routine pregnancy care at 11+0-13+6 weeks’ gestation at 
King’s College Hospital and Medway Maritime Hospital, United Kingdom. We recorded 
maternal characteristics and medical history and performed combined screening to estimate 
risks for fetal aneuploidies based on maternal age, fetal nuchal translucency (NT) thickness 
and measurement of maternal serum pregnancy associated plasma protein-A (PAPP-A) and 
free ß-human chorionic gonadotropin (hCG).2 Transabdominal colour Doppler ultrasound 
was performed to measure ductus venosus pulsatility index for veins (DV-PIV) and uterine 
artery pulsatility index (UT-PI).3,4 Gestational age was determined from measurement of fetal 
crown-rump length (CRL).5 The women were screened between March 2006 and October 
2015 and gave written informed consent to participate in the study, which was approved by 
the Ethics Committee.  
 
The inclusion criteria for the study were singleton pregnancies that delivered a 
phenotypically normal live birth or stillbirth at >24 weeks’ gestation. We excluded 
pregnancies with aneuploidies, major fetal abnormalities, those ending in a miscarriage, 
termination of pregnancy or stillbirths due to intrapartum causes. Data on pregnancy 
outcome were obtained from the maternity hospital records or the general practitioners of 
women. The hospital maternity records of all women with antepartum stillbirths were 
reviewed to determine if the death was associated with preeclampsia, abruption or the 
birthweight was <10th percentile for gestational age 6 or it was unexplained.  
 
Statistical analysis 
 
Data from continuous variables were expressed as medians and interquartile ranges and 
from categorical data as n (%). Comparison of the maternal characteristics between the 
outcome groups was by the χ2-square test or Fisher’s exact test for categorical variables 
and Kruskal-Wallis or Mann-Whitney U-test for continuous variables, respectively. A p value 
of < 0.05 was considered significant. Post-hoc Bonferroni correction was used for multiple 
comparisons. 
 
The measured fetal NT was expressed as a difference from the expected normal mean for 
fetal CRL (delta value).7 The values of serum PAPP-A and free β-hCG were log10 
transformed to make their distributions Gaussian and each measured value was expressed 
as a multiple of the normal median (MoM) after adjustment for those characteristics found to 
provide a substantial contribution to the log10 transformed value.8,9 Similarly, the observed 
measurements of ductus venosus PIV and uterine artery PI were expressed as a MoM after 
adjustment for maternal characteristics.3,10  
The a priori risk for stillbirths was estimated from the algorithm derived from multivariate 
logistic regression analysis of maternal characteristics and history as previously described.R 
Univariate and multivariate logistic regression analysis was then used to determine if the 
maternal factor-derived logit (a priori risk), log10 MoM value of each biochemical and 
biophysical marker had a significant contribution in stillbirths. The variables which provided a 
significant contribution in the multivariate analysis were used to determine the patient-
specific risk of stillbirth using the equation odds/(1+odds), where odds=eY and Y was 
estimated from the coefficients of variables in the logistic regression analysis. The 
distribution of patient-specific risks was used to determine the performance of screening by 
receiver operating characteristic (ROC) curves analysis and the DR and FPR were 
estimated.  
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) and Medcalc (Medcalc Software, Mariakerke, Belgium) 
were used for the data analyses. 
 
 
Results 
 
Study population 
 
The 76,897 singleton pregnancies fulfilling the entry criteria included 76,629 live births and 
268 (0.35%) antepartum stillbirths; 157 (59%) were secondary to impaired placentation and 
111 (41%) were due to other or unexplained causes. The maternal and pregnancy 
characteristics of the outcome groups are compared in sTable 1.  
 
Biomarkers in outcome groups 
 
In the stillbirth group, compared to live births, there was lower serum PAPP-A MoM (0.85 vs 
1.00; p<0.0001), and higher DV-PIV MoM (1.02 vs 1.00; p<0.01) and UT-PI MoM (1.25 vs 
1.00, p<0.0001), but there were no significant differences in serum free ß-hCG MoM or delta 
NT (sTable 2). Similarly, in the stillbirths due to impaired placentation, compared to live 
births, there was lower serum PAPP-A MoM (0.70 vs 1.00; p<0.0001), and higher DV-PIV 
MoM (1.05 vs 1.00; p<0.0001) and UT-PI MoM (1.41 vs 1.00, p<0.0001); in the stillbirths due 
to unexplained causes there were no significant differences from live births in any of the 
biomarkers (Figure 1). 
 
Prediction of stillbirth and performance of screening 
 
The results of univariate and multivariate regression analysis are shown in sTable 3. In the 
multivariate regression analysis, there was a significant contribution to the prediction of 
stillbirths due to impaired placentation from maternal factor derived priori risk and MoM 
values of PAPP-A, DV-PIV and UT-PI (R2=0.152; p<0.0001). 
 
The performance of screening for stillbirth is shown in Table 1. The DR for all stillbirths, at  
FPR of 10%, increased from 31% for maternal factors to 40% with addition of biomarkers 
(p=0.008). Within the impaired placentation group, the DR increased from 36% for maternal 
factors to 55% with addition of biomarkers (p<0.0001). The DR of stillbirth based on 
maternal factors and biomarkers at <32 weeks’ gestation was higher than that of stillbirths at 
>37 weeks (64% vs 41%; p=0.023). 
 
 
Conclusions 
 
Main findings of the study 
 
The findings of the study demonstrate that more than half of stillbirths due to impaired 
placentation can be predicted in the first trimester of pregnancy from a combination of 
maternal factors and biomarkers. The performance of screening is better for stillbirths 
secondary to impaired placentation compared to those that are unexplained and in the 
impaired placentation group, the DR is higher for stillbirths that occur preterm than at term. 
 
Strengths and limitations 
 
The strengths of this screening study are first, examination of a large population of pregnant 
women attending for routine assessment at 11-13 weeks’ gestation, second, systematic 
recording of data on maternal characteristics and medical history to identify known risk 
factors associated with stillbirth, third, use of a specific methodology and appropriately 
trained doctors to measure DV-PIV and UT-PI, fourth, expression of the values of 
biomarkers as MoMs after adjustment for factors that affect the measurements, and fifth, use 
of multivariate regression analysis to take into account possible interrelations between the 
different variables to define the relative predictive value of each factor. A potential limitation 
of the study is that the performance of screening by a model derived and tested using the 
same dataset is overestimated.  
 
Comparison with other studies 
 
In a previous study in 33,452 pregnancies, which included 142 stillbirths, we demonstrated 
that significant contributors to stillbirth were maternal factors, serum PAPP-A and reversed 
flow in the DV; the DR of all stillbirths was 35%, at 10% FPR.11 In this study we used a 
quantitative rather than qualitative assessment of waveforms from the DV and in addition 
included measurement of UT-PI to improve the DR to 40%. 
 
Previous studies have reported that low serum PAPP-A is associated with increased risk of 
stillbirth. In a screening study of 54,722 singleton pregnancies, including 225 stillbirths, we 
found that for PAPP-A < 0.42 MoM, which corresponds to the 5th percentile, the odds of 
having a stillbirth were increased by a factor of 1.94.12 Another screening study of 33,395 
pregnancies, including 95 stillbirths, found that for PAPP-A < 0.42 MoM, the odds of stillbirth 
were increased 2.15 fold.13  
 
We found that the risk of stillbirth increased 2.9-fold for every unit increase in DV-PIV MoM. 
We previously examined the contribution of reversed a-wave in the DV and reported that this 
finding is associated with a 2-fold increase in risk of stillbirth.14 We found that the risk of 
stillbirth increased 18-fold for every unit increase in UT-PI MoM. A previous study in 9,859 
pregnancies, including 62 stillbirths, reported that if impedance to flow in the uterine arteries 
was > 90th percentile the odds of stillbirth increased by a factor of 2.13.15  
 
Clinical implications of the study 
 
The results of our study demonstrate that more than half of the stillbirths due to impaired 
placentation can be effectively identified in the first trimester of pregnancy. Pharmacological 
interventions in the high-risk group, by such drugs as low-dose aspirin starting at <16 weeks’ 
gestation, could potentially improve placentation and reduce the associated stillbirths by 
more than 50%.17 
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Table 1. Performance of screening for stillbirths at various cut-offs of gestational age based 
on maternal factors and combination of maternal factors with biochemical and biophysical 
markers at 11-13 weeks’ gestation at fixed false positive rates (FPR). 
 
Outcome  N AUROC (95% CI) 
Detection rates (95% CI) 
5% FPR 10% FPR 
All stillbirths 268  
     Maternal factors  0.657 (0.621-0.693) 19.8 (15.0-24.6) 31.3 (25.6-36.9) 
     + PAPP-A + Ut PI + DV PIV  0.724 (0.690-0.758) 32.5 (26.9-38.1) 39.9 (34.0-45.8) 
Unexplained    
     Maternal factors 111 0.623 (0.569-0.677) 14.4 (7.9-20.9) 24.3 (16.3-32.3) 
Abnormal placentation  
All stillbirths 157    
     Maternal factors  0.681 (0.633-0.728) 23.6 (17.0-30.2) 36.3 (28.8-43.8) 
     + PAPP-A  0.732 (0.687-0.777) 32.5 (25.2-39.8) 42.0 (34.3-49.7) 
     + DV PIV  0.700 (0.654-0.747) 28.7 (21.6-35.8) 38.3 (30.7-45.9) 
     + Ut PI  0.808 (0.771-0.845) 39.5 (31.9-47.2) 50.3 (42.5-58.1) 
     + PAPP-A + DV PIV  0.745 (0.701-0.789) 36.3 (28.8-43.8) 44.6 (36.8-52.4) 
     + Ut PI + DV PIV  0.814 (0.777-0.850) 40.8 (33.1-48.5) 52.2 (44.4-60.1) 
     + PAPP-A + Ut PI  0.818 (0.781-0.856) 45.9 (38.1-53.7) 54.1 (46.3-61.9) 
     + PAPP-A + Ut PI + DV PIV  0.825 (0.788-0.861) 47.8 (40.0-55.6) 54.8 (47.0-62.6) 
< 32 weeks 90    
     Maternal factors  0.700 (0.637-0.764) 31.1 (21.5-40.7) 40.0 (29.9-50.1) 
     + PAPP-A + Ut PI + DV PIV  0.870 (0.827-0.912) 57.8 (47.6-68.0) 64.4 (54.5-74.3) 
< 37 weeks 121    
     Maternal factors  0.694 (0.641-0.748) 26.4 (18.6-34.3) 36.4 (27.8-45.0) 
     + PAPP-A + Ut PI + DV PIV  0.842 (0.801-0.883) 52.9 (44.0-61.8) 59.7 (51.0-68.4) 
> 37 weeks 36    
     Maternal factors  0.634 (0.530-0.737) 13.9 (2.6-25.2) 30.1 (15.1-45.0) 
     + PAPP-A + Ut PI + DV PIV  0.766 (0.690-0.841) 30.6 (15.6-45.7) 41.7 (25.6-57.8) 
 
AUROC=area under receiver operating characteristic curves; CI= confidence interval; FPR = 
False positive rates; PAPP-A= pregnancy associated plasma protein-A; Ut PI=Uterine artery 
pulsatility index; DV PIV = ductus venosus pulsatility index for veins 
 
 
Supplementary Table 1. Maternal and pregnancy characteristics in pregnancies that had a stillbirth, stratified according to sub-groups, 
compared with pregnancies that had a live births 
 
Maternal characteristics 
Live births 
(n=76,629) 
All stillbirths 
(n=268) 
Unexplained 
(n=111) 
Impaired placentation 
(n=157) 
Age, median (IQR) 31.3 (26.7-35.1) 31.6 (26.4-35.6) 32.6 (26.1-36.3) 30.8 (26.4-35.5) 
Weight, median (IQR) 67.0 (59.2-77.2) 73.0 (63.0-84.0)* 71.0 (62.9-83.3) † 74.0 (63.2-85.1)* 
Height, median (IQR) 1.65 (1.60-1.69) 1.65 (1.60-1.68) 1.65 (1.61-1.68) 1.64 (0.60-1.68) 
Racial origin     
     Caucasian, n (%) 54,664 (71.3) 143 (53.4) 64 (57.7) 79 (50.3) 
     Afro-Caribbean, n (%) 15,088 (19.7) 103 (38.4)* 39 (35.1)* 64 (40.8)* 
     South Asian, n (%) 3,256 (4.2) 10 (3.7) 4 (3.6) 6 (3.8) 
     East Asian, n (%) 1,576 (2.1) 4 (1.5) 1 (0.9) 3 (1.9) 
     Mixed, n (%) 2,045 (2.7) 8 (3.0) 3 (2.7) 5 (3.2) 
Method of conception     
     Spontaneous, n (%) 74,173 (96.8) 251 (93.7) 104 (93.7) 147 (93.6) 
     Assisted conception, n (%) 2,456 (3.2) 17 (6.3)† 7 (6.3) 10 (6.4) 
Cigarette smoking, n (%) 7,125 (9.3) 31 (11.6) 10 (9.0) 21 (13.4) 
Chronic hypertension, n (%) 1,075 (1.4) 18 (6.7)* 1 (0.9) 17 (10.8)* 
SLE / APS, n (%) 154 (0.2) 4 (1.5) † 0 4 (2.5)* 
Diabetes mellitus, n (%) 695 (0.9) 10 (3.7)* 5 (4.5)* 5 (3.2) † 
Parity     
     Nulliparous, n (%) 36,320 (47.4) 132 (49.3) 55 (49.5) 77 (49.0) 
     Previous miscarriage, n (%) 1,004 (1.3) 5 (1.9) 3 (2.7) 2 (1.3) 
     Previous stillbirth, n (%) 617 (0.8) 13 (4.9)* 4 (3.6) † 9 (5.7)* 
     Previous SGA, n (%) 2,486 (3.2) 13 (4.9) 3 (2.7) 10 (6.4) 
Inter-pregnancy interval, median (IQR)a 1.0 (0.0-3.1) 0.8 (0.0-4.4) 0.9 (0.0-4.0) 0.7 (0.0-4.9) 
 
Post hoc Bonferroni correction for multiple comparisons; † = p< 0.01; * = p< 0.001 
 
IQR=interquartile range; SLE=systemic lupus erythematosus; APS=anti-phospholipid syndrome; SGA= small for gestational age 
a Inter-pregnancy interval median (IQR) reported for parous women 
 
 
Supplementary Table 2. Median and interquartile range of biochemical and biophysical markers in pregnancies with livebirths compared to 
those that had a stillbirth 
Biomarker 
Livebirths 
(n=76,629) 
All stillbirths 
(n=268) 
Unexplained 
(n=111) 
Abnormal placentation 
(n=157) 
Pregnancy associated plasma protein-A (MoM) 1.00 (0.69-1.43) 0.85 (0.53-1.24)*** 1.04 (0.71-1.44) 0.70 (0.46-1.13)*** 
Free β-human chorionic gonadotropin (MoM) 1.00 (0.68-1.52) 1.06 (0.63-1.50) 1.10 (0.67-1.49) 0.98 (0.61-1.59) 
Ductus venosus pulsatility index (MoM) 1.00 (0.90-1.10) 1.02 (0.92-1.15)** 1.02 (0.91-1.11) 1.05 (0.94-1.19)*** 
Delta fetal nuchal translucency 0.00 (-0.19-0.22) -0.01 (-0.18-0.23) 0.07 (-0.16-0.25) -0.03 (-0.19-0.19) 
Uterine artery pulsatility index (MoM) 1.00 (0.81-1.21) 1.25 (0.97-1.55)*** 1.02 (0.83-1.28) 1.41 (1.16-1.66)*** 
 
MoM= multiple of the median 
 
Supplementary Table 3. Univariate and multivariate logistic regression analysis for the 
prediction of stillbirths due to impaired placentation by maternal factors and biomarkers at 
11-13 weeks’ gestation 
 
 
PAPP-A = pregnancy associated plasma protein-A; hCG = human chorionic gonadotropin; 
PI = pulsatility index; PIV = pulsatility index for veins; MoM= multiple of the median; OR = 
odds ratio; CI = confidence interval 
  
Variables 
Univariate analysis Multivariate analysis 
OR (95% CI) P value OR (95% CI) P value 
Maternal factor derived logit (a priori risk) 16.27 (10.46-25.31) <0.0001 12.93 (8.12-20.57) <0.0001 
Log10 PAPP-A MoM 0.18 (0.13-0.27) <0.0001 0.25 (0.16-0.40) <0.0001 
Log10 free β-hCG MoM 0.93 (0.51-1.69) 0.814   
Delta fetal nuchal translucency 0.89 (0.58-1.35) 0.575   
Log10 ductus venosus PIV MoM 193.15 (41.73-894.00) <0.0001 75.73 (15.65-366.48) <0.0001 
Log10 uterine artery PI MoM 14.13e03 (3.53e03-56.51e03) <0.0001 5.13e03 (1.26e03-20.91e03) <0.0001 
Figure 1. Box and whiskers plot of pregnancy associated plasma protein-A multiple of the 
median (MoM), uterine artery pulsatility index (PI) MoM and ductus venosus (DV) PIV MoM 
in live births (a), unexplained stillbirths (b) and stillbirths due to impaired placentation (c). 
The bottom and top edges of each box represent the first and third quartiles, respectively; 
the band within the box represents the median value. 
   
Figure 2. Receiver–operating characteristics curves for prediction of stillbirth due to impaired 
placentation from maternal factors and maternal factors with biomarkers. 
 
